Skip to main content

Entrada Therapeutics, Inc.

For the period ended Jun 30, 2026. Filed Aug 5, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 5, 2026

TRDA$4.69-4.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Balance Sheets

(In thousands, except share and per share amounts)

June 30,2026December 31,2025
Assets
Current assets:
Cash and cash equivalents$99,280$90,394
Marketable securities123,725205,304
Restricted cash, current portion—658
Collaboration receivable8161,177
Prepaid expenses and other current assets8,8838,719
Total current assets232,704306,252
Property and equipment, net5,7227,313
Restricted cash3,2923,292
Right-of-use assets, operating leases57,04160,451
Other non-current assets11870
Total assets$298,877$377,378
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable$3,746$2,289
Accrued expenses and other current liabilities13,00317,682
Operating lease obligations, current portion4,4494,138
Deferred revenue173342
Total current liabilities21,37124,451
Operating lease obligations, net of current portion44,09546,794
Total liabilities65,46671,245
Commitments and contingencies (Note 11)
Stockholders' equity:
Common stock, par value $0.0001; 150,000,000 shares authorized; 38,936,669 shares issued and outstanding as of June 30, 2026; and 38,284,221 shares issued and outstanding as of December 31, 202544
Additional paid‑in capital588,915578,571
Accumulated other comprehensive income66652
Accumulated deficit(355,574)(273,094)
Total stockholders' equity233,411306,133
Total liabilities and stockholders' equity$298,877$377,378
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.